Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Article information

Korean J Intern Med. 2023;38(2):157-166

Publication date (electronic) : 2023 February 6

doi : https://doi.org/10.3904/kjim.2022.271

¹Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea

³Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

Correspondence to: Mi-Seung Shin, M.D., Ph.D., Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea, Tel: +82-32-460-3663, Fax: +82-32-469-1906, E-mail: msshin@gilhospital.com

Received 2022 August 21; Revised 2022 December 21; Accepted 2023 January 1.

Abstract

The prevalence of heart failure with preserved ejection fraction (HFpEF) has increased in recent decades. In particular, obesity-related HFpEF is a distinct and frequently encountered phenotype; however, its diagnosis is complex. Furthermore, the management of obesity-related HFpEF has not been established despite the introduction of promising drugs. This review summarizes the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF.

Keywords: Obesity; Heart failure; Dyspnea; Diagnosis; Treatment

INTRODUCTION

The prevalence of heart failure is increasing rapidly in Korea and worldwide as a result of an aging society and an increase in cardiometabolic comorbidities [1,2]. Approximately 1.2 million Korean adults have developed heart failure as of 2018, and its prevalence has increased nearly three-fold from 2002 to 2018 [2]. Heart failure is categorized into three subtypes based on the left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF; LVEF ≤ 40%), heart failure with mildly reduced ejection fraction (40 < LVEF < 50%), and heart failure with preserved ejection fraction (HFpEF; LVEF ≥ 50%). Although categorizing heart failure based on the LVEF is arbitrary (considering the continuous nature of LVEF), the pathophysiology and treatment response of HFrEF and HFpEF are different.

HFpEF is increasing in incidence and emerging as a major health problem [3,4]. A Mayo Clinic study reported an increase in the prevalence of HFpEF over 15 years (from 38% to 54%). More recent data from the Framingham study also revealed a similar increase in the prevalence of HFpEF over three decades (from 41% to 56.2%). Despite the continued improvement in the survival of patients with HFrEF after the introduction of effective therapeutics, the survival of patients with HFpEF remains poor [3]. Most clinical trials of therapeutic agents, except for those of sodium-glucose cotransporter-2 inhibitors (SGLT2i), have failed to demonstrate improved survival among patients with HFpEF. This is partly because HFpEF is a heterogeneous syndrome with a variety of comorbidities [5]; thus, identifying different HFpEF phenotypes and targeting therapy based on the phenotype may be an effective strategy. Among the various subtypes of HFpEF, obesity-related HFpEF is distinct and common [6], but its diagnostic and therapeutic approaches in practice are complex. In this review, we discuss the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF using a clinical vignette.

DIAGNOSTIC CHALLENGES OF HFpEF IN OBESE INDIVIDUALS

Clinical vignette

An 80-year-old female with progressive shortness of breath during daily activities visited the outpatient clinic. She had been on antihypertensive medication for 10 years. Her body mass index (BMI) was 31.2 kg/m² and her waist circumference was 111 cm. Computed tomography revealed prominent visceral fat (Fig. 1A). Electrocardiography revealed a normal sinus rhythm. Her initial N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was 109.0 pg/mL (reference < 300 pg/mL). Coronary computed tomography angiography revealed no significant stenosis, and the calcium score was 0. Transthoracic echocardiography showed preserved left ventricular systolic function (LVEF 64%) with grade 1 diastolic dysfunction (E/A ratio 0.7, septal/lateral e’ 7.3/7.9 cm/s, average E/e’ 11.1, left atrial volume index 38.1 mL/m², and tricuspid regurgitation [TR] V_max 2.7 m/s) and concentric left ventricular (LV) hypertrophy (LV mass index, 106.8 g/m²; relative wall thickness, 0.48). We were unsure whether the patient fulfilled the diagnostic criteria for HFpEF and how to manage this case.

Figure 1

Clinical vignette of an obese woman with exertional dyspnea. (A) Note the prominent visceral fat (pericardial or mesentery fat), indicated by the yellow asterisks. (B) The usefulness of exercise echocardiography in the diagnosis of heart failure with preserved ejection fraction. The patient underwent bicycle exercise echocardiography with an initial workload of 25 W and a 25 W increase in workload every 3 minutes. She terminated exercise because of dyspnea immediately after beginning 50 W (total exercise time 3 minutes). Even under low-grade exercise (25 W), inversion of the E/A ratio and rapid elevation of the E/e’ ratio (reflecting high left ventricular filling pressure) and maximal velocity of TR were observed. TR, tricuspid regurgitation.

Diagnostic approach

Establishing an HFpEF diagnosis is challenging in patients with unexplained exertional dyspnea but no clear evidence of hypervolemia. This is particularly true in obese individuals. Although the gold standard for diagnosing HFpEF is cardiac catheterization, this method requires admission and invasive procedures, making it unsuitable for practical application in a large population. Two scoring systems (H₂FPEF score and the Heart Failure Association [HFA]-PEFF score) have been suggested to facilitate HFpEF diagnosis (Fig. 2) [7,8]. Intriguingly, these two scoring systems can differentially affect the diagnosis of obesity-related HFpEF.

Figure 2

Diagnostic approach for heart failure with preserved ejection fraction. HFpEF, heart failure with preserved ejection fraction; AF, atrial fibrillation; TR, tricuspid regurgitation; PASP, pulmonary artery systolic pressure; LAVI, left atrial volume index; LVMI, left ventricular mass index; RWT, relative wall thickness; NT-proBNP, N-terminal pro-B-type natriuretic peptide; BNP, B-type natriuretic peptide; GLS, global longitudinal strain; LV, left ventricle.

First, the H₂FPEF score from the Mayo Clinic is composed of four clinical parameters (obesity, hypertension, atrial fibrillation, and old age) and two echocardiographic parameters (E/e’ and pulmonary artery systolic pressure) [7]. This system does not require information about biomarkers (such as NT-proBNP). Here, obesity (defined as BMI ≥ 30 kg/m²) is allocated 2 points, increasing the possibility of HFpEF diagnosis in obese patients. Several community-based studies, including those from Asia, have demonstrated acceptable diagnostic and prognostic yields of the H₂FPEF scoring system [9,10]. However, the appropriate BMI cutoff value for Asian populations, who have a lower BMI than Western populations, should be investigated separately.

Second, the HFA-PEFF score is determined based on three domains of heart function (functional, morphological, and biomarker domains) [8,11]. The HFA-PEFF score is based on nine echocardiographic parameters, which increases the complexity. The threshold NT-proBNP level is ≥ 125 pg/mL for sinus rhythm and ≥ 365 pg/mL for atrial fibrillation; however, obesity is associated with a low circulating natriuretic peptide level [6,12,13]. Thus, a caveat is needed when interpreting the HFA-PEFF score in obese individuals.

Additionally, we should consider that both scoring systems are not perfect for diagnosing HFpEF [14]. Accordingly, performing additional exercise echocardiography or invasive catheterization is mandatory in highly suspicious cases and should also be performed for obese individuals [7,8,15–17]. Many patients with HFpEF exhibit normal or marginally elevated LV filling pressure at rest (E/e’, 9–14) and only elevated LV filling pressure during exercise [15]. A recent trend in HFpEF diagnosis is to increase the sensitivity to HFpEF by lowering the LV filling pressure cutoff (resting E/e’, > 9). The latest European guidelines lowered the E/e’ cutoff from 13 to 9. Moreover, the E/e’ cutoff in the HFpEF scoring systems should be > 9 [7,8,16]. The index case patient had discordant results based on the scoring system: the H₂FPEF score was 7 (confirmatory), but the HFA-PEFF score was 4 (indeterminate). Although she qualified as HFpEF based on the H₂FPEF score, we planned additional confirmatory exercise echocardiography testing considering her relatively low average E/e’ and NT-proBNP levels. The E/A ratio was reversed immediately after initiating exercise (low-grade 25 W exercise), and the average E/e’ ratio increased from 11 to 17 and the pulmonary artery pressure increased from 39.2 to 67.8 mmHg (Fig. 1B). As illustrated in this case, exercise echocardiography revealed an impaired diastolic reserve during exercise, which is the primary pathophysiology of HFpEF.

A poor echocardiographic window in obese individuals is a hurdle in the diagnosis of HFpEF. Moreover, obese elderly people frequently have arthralgia when performing exercise tests, particularly a treadmill test. However, in this case, bicycle echocardiography with low-grade exercise may be a good option. Previous studies have demonstrated that rapid changes in hemodynamic parameters during the early stages of exercise (25 W, which can be performed by almost all participants) are important kinetic properties [17–19]. The recommended exercise echocardiographic evidence for elevated LV filling pressure is peak E/e’ ≥ 15 and/or peak TR velocity > 3.4 m/s according to the 2021 European Society of Cardiology heart failure guidelines [16]. However, various exercise echocardiographic parameters with different cut-offs (septal E/e’ > 15 or average E/e’ > 14 and peak TR velocity > 2.8 m/s) have been suggested by other guidelines and studies [16,17,20]. Therefore, further studies are needed to verify the appropriate diagnostic criteria for HFpEF based on obesity and ethnicity.

PATHOPHYSIOLOGY OF OBESITY-RELATED HFpEF

Obesity contributes to the occurrence of HFpEF via multiple pathways (Fig. 3). Among them, sodium retention and systemic inflammation are the main drivers of HFpEF in individuals with obesity. Renal tubular sodium retention and plasma volume expansion occur in obese people due to the overproduction of aldosterone and enhanced degradation of natriuretic peptides [6,21–26]. Adipocytes directly synthesize aldosterone and indirectly enhance aldosterone secretion from the adrenal gland by releasing leptin and catecholamines [25,26]. Adipocytes are also associated with increased expression of neprilysin, which enhances the degradation of natriuretic peptides, which in turn increases the lelvel of aldosterone. Adipose tissue in obese individuals undergoes a shift to a pro-inflammatory state, which contributes to the stiffening of the heart and vessels via extracellular matrix remodeling, thrombosis, and inflammation. Unlike subcutaneous fat (which is often regarded as quiescent fat), visceral fat, particularly that surrounding the heart and vessels, exerts deleterious effects by secreting pro-inflammatory adipokines. Among the different visceral fat types, epicardial adipose tissue is currently considered an important target in HFpEF [27–29]. Beyond its inflammatory action, epicardial and pericardial fat inhibits cardiac distensibility by acting as a mechanical restraint [6]. Obesity is commonly associated with comorbidities, such as hypertension, diabetes, and obstructive sleep apnea, all of which can lead to HFpEF.

Figure 3

Pathophysiology of obesity-related heart failure with preserved ejection fraction. RA, right atrium; RV, right ventricle; Ao, aorta; LA, left atrium; LV, left ventricle; HFpEF, heart failure with preserved ejection fraction.

The heart can accommodate the expanded volume by dilating the LV under normal conditions. However, a stiffened heart due to inflammation in the case of obese HFpEF cannot adequately accommodate the expanded volume due to the obesity, ultimately resulting in elevated LV filling pressure, even at low levels of physical activity [24]. In particular, obesity is closely related to increased LV filling pressure in women [28,30–32]. The exact mechanisms behind the sex-specific association remain unclear. However, fat-pre-dominant body composition (higher fat at a given BMI) and higher LV filling pressure, even with the same amount of fat, in females may be causes. Further studies of female pre-dominance in obese patients with HFpEF are needed.

THERAPEUTIC OPTIONS

Lifestyle modifications: caloric restriction and exercise

Several studies have reported the benefits of caloric restriction and exercise on LV diastolic function and/or exercise capacity [33–35]. In a small, well-designed randomized clinical trial, Kitzman et al. [34] demonstrated that caloric restriction or aerobic exercise increases exercise capacity (expressed as peak VO₂), and the effect of caloric restriction and aerobic exercise may be synergistic in older obese patients with stable HFpEF. However, the effect of weight loss may be transient, and weight gain after intentional weight loss (the so-called yo-yo effect) is frequent in the real world. Therefore, a more predictable and sustainable approach to weight control (either medical or surgical) is required.

Bariatric surgery

Most obese Asian patients with HFpEF (corresponding BMI 25–35 kg/m²), whom we frequently encounter in practice, may not be candidates for bariatric surgery. However, HFpEF with severe obesity (BMI ≥ 40 kg/m²) is frequently observed in Western countries [36–38]. In one study, bariatric surgery alleviated exertional dyspnea and leg edema in heart failure patients with severe obesity (median BMI, 55 kg/m²) [36]. One study included only obese women with HFpEF (mean BMI, 43.9 kg/m²) and found that bariatric surgery was associated with weight loss, improved symptoms, reverse heart remodeling, and improved cardiac relaxation [38].

Medications that ameliorate the adverse effects of obesity on the heart

Although the diagnosis of HFpEF can be obtained via complex process and test, the available treatment options are limited. However, according to the results of The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) [39] and Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) [40] trials, SGLT2i should be considered in individuals with HFpEF. The salutary effects of SGLT2i appear to be similarly applicable to those of obese and non-obese HFpEF patients [39,40]. Despite the distinct benefit to heart failure, the mechanism behind how SGLT2i lead to cardiovascular (CV) benefits is not fully understood. Considering the early CV benefit that occurs within 1 month, pleiotropic effects, beyond the glucose-lowering effect, are gaining more attention [41–43]. SGLT2i modulate two main pathophysiologies of obesity-related HFpEF (sodium retention and systemic inflammation) via hemodynamic and metabolic pathways (Fig. 4). The natriuresis-driven effect is the mainstay from a hemodynamic perspective and is thought to also play an important role in obese HFpEF by addressing obesity-related sodium retention. Decreased sodium reabsorption by SGLT2i leads to an increased sodium concentration in the macular densa, which activates tubuloglomerular feedback and constricts the afferent glomerular arterioles. Consequently, there is a decrease in intraglomerular pressure and renal protection. Additionally, natriuresis is associated with decreased plasma volume (approximately 7% reduction) and blood pressure (4/2 mmHg reduction in systolic/diastolic blood pressure), which can be translated into decreased preload and afterload of the heart [42–46]. SGLT2i-induced glucosuria is another important axis in resolving HFpEF pathophysiology. SGLT2i are associated with a negative caloric balance via the excretion of 200–250 kcal/day in the urine, which reduces body weight (approximately 2–3 kg) [44,46]. Weight loss with SGLT2i use appears to be accompanied by a reduction in body fat and extracellular fluid but does not affect lean mass [47]. Furthermore, a lower glucose level decreases insulin resistance and enhances the secretion of glucagon, leading to lipolysis in adipose tissue. The increased free fatty acids are taken up by the liver, where they undergo oxidation and are converted to acetyl-CoA and ketone bodies. The high ketone body production and metabolism favorably contribute to CV and renal outcomes by acting as an efficient energy substrate and improving mitochondrial respiration (adenosine triphosphate hydrolysis), although this hypothesis warrants further studies [48–54]. Moreover, these metabolic changes help alleviating obesity-related inflammation and fibrosis [50–53]. Taken together, these findings beneficially affect the kidney and heart individually and via cardio-renal interaction.

Figure 4

The postulated mechanism of the benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for obesity-related heart failure with preserved ejection fraction. The effects of SGLT2i according to their hemodynamic and metabolic actions are summarized. Collectively, these mechanisms synergistically and positively affect kidney and heart outcomes. Furthermore, cardio-renal interactions that lead to a virtuous cycle are linked to a favorable outcome. The overall effect of SGLT2i appears to be similar between obese and non-obese individuals with heart failure with preserved ejection fraction.

Considering that sodium retention and high aldosterone levels are frequently found in obesity-related HFpEF, mineralocorticoid receptor antagonists (MRAs) may be a good therapeutic option. Among the diverse HFpEF phenotypes, MRAs are associated with reduced risks of CV death, hospitalization for heart failure, and aborted cardiac arrest in patients with obesity-related HFpEF [55]. In the TOPCAT trial (Aldosterone Antagonist Therapy for Adults with Heart Failure and Preserved Systolic Function), subgroup analyses according to BMI category revealed a significant risk reduction in the primary endpoints (CV death and hospitalization for heart failure) in the obese groups (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.66–0.98) [56]. Moreover, the effect of obesity on the response to spironolactone in patients with HFpEF was explicitly explored in post hoc analyses of the TOPCAT American cohort [57]. In that study, obesity was defined by either BMI or waist circumference, and spironolactone was associated with a significant risk reduction in CV death or hospitalization for heart failure in obese patients but not in non-obese subjects (HR, 0.618; 95% CI, 0.460–0.831 in those with BMI ≥ 30 kg/m² compared with their counterparts; HR, 0.740; 95% CI, 0.559–0.980 in those with a large waist circumference compared with their counterparts). However, further randomized trials evaluating obese HFpEF are required to clarify the effect of MRAs on clinical outcomes.

Neprilysin inhibitors are expected to have beneficial effects, given the deficiency of natriuretic peptides in patients with obesity-related HFpEF. However, the PARAGON-HF trial reported no significant CV benefit of sacubitril-valsartan over valsartan in HFpEF subjects [58,59]. The treatment interaction based on sex and LVEF is controversial. Furthermore, that study was designed to compare the effect of sacubitril-valsartan against an active comparator (valsartan), which may have affected the results. A putative placebo analysis showed the potential benefit of sacubitril–valsartan compared with a putative placebo (HR, 0.71; 95% CI, 0.54–0.93) [60]. Individuals with severe obesity (BMI > 40 kg/m²) were excluded at enrollment, which limited the conclusions that could be drawn regarding the drug effect in obese patients with HFpEF.

A summary of recent clinical trials of these three medications in obesity-related HFpEF is presented in Table 1. It is important to remember when interpreting the results of recent HFpEF clinical trials that the inclusion criteria for HFpEF differed somewhat from the definition of HFpEF stated in guidelines and/or the characteristics of real-world HFpEF patients. Indeed, a substantial number of patients with a LVEF of 40–49% (which falls into the heart failure with mildly reduced EF category) were enrolled in the study. Furthermore, more advanced-stage HFpEF (history of hospitalization) and less obese patients may have been preferentially included in the study to meet the requirement of an elevated NT-proBNP. Subsequent subgroup-specific randomized clinical and prospective cohort studies are required to clarify the effects of these drugs.

Table 1

Summary of recent clinical trials of HFpEF patients: overall and obesity-specific results

CONCLUSIONS

Obesity-related HFpEF is a distinct entity of HFpEF with a unique pathophysiology. However, decreased natriuretic peptide levels and a poor echocardiographic window in obese patients often hamper the diagnosis. Exercise stress echocardiography may be helpful when the HFpEF diagnosis is uncertain. There are promising new drugs for HFpEF, although additional clinical trials are needed to identify the best combination of medications and determine how these drugs can modulate the pathophysiology of obesity-related HFpEF.

Notes

No potential conflict of interest relevant to this article was reported.

References

1. Park JJ, Choi DJ. Current status of heart failure: global and Korea. Korean J Intern Med 2020;35:487–497.

2. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224–236.

3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.

4. Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging 2018;11:1–11.

5. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016;134:73–90.

6. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19.

7. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861–870.

8. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–3317.

9. Hwang IC, Cho GY, Choi HM, et al. H2FPEF score reflects the left atrial strain and predicts prognosis in patients with heart failure with preserved ejection fraction. J Card Fail 2021;27:198–207.

10. Tada A, Nagai T, Omote K, et al. Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: a report from the Japanese multicenter registry. Int J Cardiol 2021;342:43–48.

11. Egashira K, Sueta D, Komorita T, et al. HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. Korean J Intern Med 2022;37:96–108.

12. Ndumele CE, Matsushita K, Sang Y, et al. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the atherosclerosis risk in communities (ARIC) study. Circulation 2016;133:631–638.

13. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590–1595.

14. Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail 2020;8:640–653.

15. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation 2017;135:825–838.

16. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.

17. Ha JW, Andersen OS, Smiseth OA. Diastolic stress test: invasive and noninvasive testing. JACC Cardiovasc Imaging 2020;13(1 Pt 2):272–282.

18. Jung MH, Jung HO, Lee JW, Youn HJ. Decreases in left atrial compliance during early-stage exercise are related to exercise intolerance in asymptomatic significant mitral stenosis. Echocardiography 2017;34:1633–1639.

19. Lewis GD, Murphy RM, Shah RV, et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4:276–285.

20. Lancellotti P, Pellikka PA, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191–1229.

21. Pandey A, Patel KV, Vaduganathan M, et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail 2018;6:975–982.

22. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116:991–1006.

23. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600.

24. Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC Heart Fail 2018;6:633–639.

25. Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069–1078.

26. Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015;132:2134–2145.

27. Kenchaiah S, Ding J, Carr JJ, et al. Pericardial fat and the risk of heart failure. J Am Coll Cardiol 2021;77:2638–2652.

28. Rao VN, Bush CG, Mongraw-Chaffin M, et al. Regional adiposity and risk of heart failure and mortality: the Jackson heart study. J Am Heart Assoc 2021;10:e020920.

29. Ayton SL, Gulsin GS, McCann GP, Moss AJ. Epicardial adipose tissue in obesity-related cardiac dysfunction. Heart 2022;108:339–344.

30. Jung MH, Ihm SH, Park SM, et al. Effects of sarcopenia, body mass indices, and sarcopenic obesity on diastolic function and exercise capacity in Koreans. Metabolism 2019;97:18–24.

31. Lee SY, Jung MH. Sex-related differences among young adults with heart failure: Does sex matter? Int J Cardiol 2022;364:91–92.

32. Jung MH, Ihm SH, Lee DH, et al. Sex-specific associations of obesity with exercise capacity and diastolic function in Koreans. Nutr Metab Cardiovasc Dis 2021;31:254–262.

33. Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol 2006;47:398–402.

34. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2016;315:36–46.

35. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 2015;8:33–40.

36. Miranda WR, Batsis JA, Sarr MG, et al. Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure. Obes Surg 2013;23:1011–1015.

37. Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. J Am Coll Cardiol 2016;67:895–903.

38. Mikhalkova D, Holman SR, Jiang H, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring) 2018;26:284–290.

39. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461.

40. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 2021;27:1954–1960.

41. Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 2017;136:1548–1559.

42. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:422–434.

43. Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med 2022;386:2024–2034.

44. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020;17:761–772.

45. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853–862.

46. Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016;11:e0166125.

47. Schork A, Saynisch J, Vosseler A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol 2019;18:46.

48. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016;65:1190–1195.

49. Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 2018;3:575–587.

50. Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail 2021;9:578–589.

51. Mullens W, Martens P. Empagliflozin-induced changes in epicardial fat: the centerpiece for myocardial protection? JACC Heart Fail 2021;9:590–593.

52. Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation 2020;141:2095–2105.

53. Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med 2020;6:186.

54. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 2017;31:119–132.

55. Cohen JB, Schrauben SJ, Zhao L, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail 2020;8:172–184.

56. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.

57. Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol 2021;146:36–47.

58. Choi HM, Shin MS. Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence. Korean J Intern Med 2020;35:498–513.

59. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–1620.

60. Vaduganathan M, Jhund PS, Claggett BL, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J 2020;41:2356–2362.

Article information Continued

(open-access) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

	Empagliflozin	Dapagliflozin	Spironolactone	Sacubitril-valsartan

	EMPEROR-Preserved (n = 5,988)	DELIVER (n = 6,263)	TOPCAT (n = 3,445)	PARAGON-HF (n = 4,822)
Drug class	SGLT2 inhibitor	SGLT2 inhibitor	Mineralocorticoid receptor antagonist	Angiotensin receptor-neprilysin inhibitor

Age, yr	Mean: 71.8	Mean: 71.7	Median: 68.7	Mean: 72.7

Female sex	2,676 (44.7)	2,742 (43.9)	1,775 (51.5)	2,479 (51.4)

BMI, kg/m²	Mean: 29.8 BMI ≥ 30 kg/m²: 2,692 (45.0)	Median: 29.8 BMI ≥ 30 kg/m²: 2,787 (44.5)	Median: 31 BMI ≥ 31 kg/m²: 1,719 (49.9)	Mean: 30.2

LVEF, %	Median: 54.3	Mean: 54.2	Median: 56	Mena: 60

LVEF ≥ 50%	4,005 (66.9)	4,147 (66.2)	2,924 (84.9)	Not provided (LVEF ≥ 45% were included)

NT-proBNP, pg/mL	Median: 944	Median: 1,011	Median: 887	Median: 911

Study duration, yr	Median: 2.2	Median: 2.3	Mean: 3.3	Median: 2.9

Comparator	Placebo	Placebo	Placebo	Valsartan

Definition of primary endpoint	Composite of CV death or HF hospitalization	Composite of CV death or HF hospitalization	Composite of CV death, aborted cardiac arrest, or HF hospitalization	Composite of CV death or HF hospitalization

Results	Success to show benefit over placebo: HR 0.79 (95% CI, 0.69–0.90)	Success to show benefit over placebo: HR 0.82 (95% CI, 0.73–0.92)	Fail to show benefit over placebo: HR 0.89 (95% CI, 0.77–1.04)	Fail to show benefit over valsartan: HR 0.87 (95% CI, 0.75–1.01)